How may targeted proteomics complement genomic data in breast cancer?

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–10874.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–8423.
   PubMed Web of Science ®Google Scholar
• Kobold DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61–70.
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–4274.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–119.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791.
   PubMed Web of Science ®Google Scholar
• Andre F, O’Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:580–591.
   PubMed Web of Science ®Google Scholar
• Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12:1597–1611.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Bahleda R, Tolaney SM, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014;32:68–75.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30:282–290.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–750.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22:1736–1747.
   PubMed Web of Science ®Google Scholar
• Akbani R, Ng PK, Werner HM, et al. A pan-cancer proteomic perspective on the cancer Genome Atlas. Nat Commun. 2014;5:3887.
   PubMed Web of Science ®Google Scholar
• Lawrence RT, Perez EM, Hernandez D, et al. The proteomic landscape of triple-negative breast cancer. Cell Rep. 2015;11:630–644.
   PubMed Web of Science ®Google Scholar
• Moghaddas Gholami A, Hahne H, Wu Z, et al. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 2013;4:609–620.
   PubMed Web of Science ®Google Scholar
• Tyers M, Mann M. From genomics to proteomics. Nature. 2003;422:193–197.
   PubMed Web of Science ®Google Scholar
• Dittrich J, Becker S, Hecht M, et al. Sample preparation strategies for targeted proteomics via proteotypic peptides in human blood using liquid chromatography tandem mass spectrometry. Proteomics Clin Appl. 2015;9:5–16.
   PubMed Web of Science ®Google Scholar
• Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods. 2013;10:28–34.
   PubMed Web of Science ®Google Scholar
• Burnette WN. “Western blotting”: electrophoretic transfer of proteins from sodium dodecyl sulfate–polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981;112:195–203.
   PubMed Web of Science ®Google Scholar
• Aebersold R, Burlingame AL. Bradshaw RA Western blots versus selected reaction monitoring assays: time to turn the tables? Mol Cell Proteomics. 2013;12:2381–2382.
   PubMed Web of Science ®Google Scholar
• Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry. 1971;8:871–874.
   PubMedGoogle Scholar
• Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem. 2002;48:1194–1197.
   PubMed Web of Science ®Google Scholar
• Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116–128.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Schmitt M, Meisner C, et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013;49:1825–1835.
   PubMed Web of Science ®Google Scholar
• Lang DS, Heilenkotter U, Schumm W, et al. Optimized immunohistochemistry in combination with image analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer. Breast. 2013;22:736–743.
   PubMed Web of Science ®Google Scholar
• Matos LL, Trufelli DC, de Matos MG, et al. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights. 2010;5:9–20.
   PubMedGoogle Scholar
• Allred DC. Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer? Am J Clin Pathol. 1993;99:1–3.
   PubMed Web of Science ®Google Scholar
• Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545–1554.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Jasani B, Balaton AJ, et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000;53:688–696.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712.
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North central cancer treatment group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–3038.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273–4278.
   PubMed Web of Science ®Google Scholar
• Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20:1981–1989.
   PubMed Web of Science ®Google Scholar
• Charboneau L, Tory H, Chen T, et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic. 2002;1:305–315.
   PubMedGoogle Scholar
• Akbani R, Becker KF, Carragher N, et al. Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society. Mol Cell Proteomics. 2014;13:1625–1643.
   PubMed Web of Science ®Google Scholar
• Boellner S, Becker KF. Reverse phase protein arrays-quantitative assessment of multiple biomarkers in biopsies for clinical use. Microarrays (Basel). 2015;4:98–114.
   PubMedGoogle Scholar
• Becker KF, Schott C, Hipp S, et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol. 2007;211:370–378.
   PubMed Web of Science ®Google Scholar
• Berg D, Langer R, Tran K, et al. Protein microarray-based comparison of HER2, estrogen receptor, and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues. Appl Immunohistochem Mol Morphol. 2011;19:300–305.
   PubMedGoogle Scholar
• Berg D, Wolff C, Malinowsky K, et al. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR. J Cell Physiol. 2012;227:204–212.
   PubMed Web of Science ®Google Scholar
• Cicenas J, Urban P, Kung W, et al. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer. 2006;42:636–645.
   PubMed Web of Science ®Google Scholar
• Frogne T, Laenkholm AV, Lyng MB, et al. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009;11:R11.
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Berg D, Wolff C, et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res. 2012;18:6426–6435.
   PubMed Web of Science ®Google Scholar
• Malinowsky K, Raychaudhuri M, Buchner T, et al. Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues. PLoS One. 2012;7:e40285.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Lu Y, Gonzalez-Angulo AM, et al. A Technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics. 2010;6:129–151.
   PubMedGoogle Scholar
• Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116–4124.
   PubMed Web of Science ®Google Scholar
• Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22:3205–3212.
   PubMed Web of Science ®Google Scholar
• Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004;10:7031–7042.
   PubMed Web of Science ®Google Scholar
• Stassi G, Garofalo M, Zerilli M, et al. PED mediates AKT-dependent chemoresistance in human breast cancer cells. Cancer Res. 2005;65:6668–6675.
   PubMed Web of Science ®Google Scholar
• Aichler M, Walch A. MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Invest. 2015;95:422–431.
   PubMed Web of Science ®Google Scholar
• Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem. 1997;69:4751–4760.
   PubMed Web of Science ®Google Scholar
• Stoeckli M, Chaurand P, Hallahan DE, et al. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med. 2001;7:493–496.
   PubMed Web of Science ®Google Scholar
• Gemoll T, Roblick UJ, Habermann JK. MALDI mass spectrometry imaging in oncology (Review). Mol Med Rep. 2011;4:1045–1051.
   PubMed Web of Science ®Google Scholar
• Pineau C. MALDI imaging mass spectrometry: applications, limitations and potential. Farm Animal Proteomics. 2013;34–35.
   Google Scholar
• Rauser S, Marquardt C, Balluff B, et al. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res. 2010;9:1854–1863.
   PubMed Web of Science ®Google Scholar
• Reyzer ML, Caldwell RL, Dugger TC, et al. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res. 2004;64:9093–9100.
   PubMed Web of Science ®Google Scholar
• Winkelmann I, Walch A, Grüner BM, et al. FAST-SRM: a new single reaction monitoring method for fast, targeted drug distribution testing in tissue sections. Bruker Daltonics application note MT-103. 2010.
   Google Scholar
• Domon B, Aebersold R. Options and considerations when selecting a quantitative proteomics strategy. Nat Biotechnol. 2010;28:710–721.
   PubMed Web of Science ®Google Scholar
• Deutsch EW. Lam H, Aebersold R. PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep. 2008;9:429–434.
   PubMed Web of Science ®Google Scholar
• Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009;27:633–641.
   PubMed Web of Science ®Google Scholar
• Muraoka S, Kume H, Watanabe S, et al. Strategy for SRM-based verification of biomarker candidates discovered by iTRAQ method in limited breast cancer tissue samples. J Proteome Res. 2012;11:4201–4210.
   PubMed Web of Science ®Google Scholar
• Liu NQ, Dekker LJ, Stingl C, et al. Quantitative proteomic analysis of microdissected breast cancer tissues: comparison of label-free and SILAC-based quantification with shotgun, directed, and targeted MS approaches. J Proteome Res. 2013;12:4627–4641.
   PubMed Web of Science ®Google Scholar
• Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002;1:376–386.
   PubMed Web of Science ®Google Scholar
• Hanke S, Besir H, Oesterhelt D, et al. Absolute SILAC for accurate quantitation of proteins in complex mixtures down to the attomole level. J Proteome Res. 2008;7:1118–1130.
   PubMed Web of Science ®Google Scholar
• Schoenherr RM, Whiteaker JR, Zhao L, et al. Multiplexed quantification of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometry. Proteomics. 2012;12:1253–1260.
   PubMed Web of Science ®Google Scholar
• Sjostrom M, Ossola R, Breslin T, et al. A Combined Shotgun and Targeted Mass Spectrometry Strategy for Breast Cancer Biomarker Discovery. J Proteome Res. 2015;14(7):2807-2818.
   PubMed Web of Science ®Google Scholar
• Steiner C, Tille JC, Lamerz J, et al. Quantification of HER2 by targeted mass spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) breast cancer tissues. Mol Cell Proteomics. 2015;14:2786–2799.
   PubMed Web of Science ®Google Scholar
• Nuciforo P, Thyparambil S, Aura C, et al. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol. 2016;10:138–147.
   PubMed Web of Science ®Google Scholar
• Trinidad JC, Specht CG, Thalhammer A, et al. Comprehensive identification of phosphorylation sites in postsynaptic density preparations. Mol Cell Proteomics. 2006;5:914–922.
   PubMed Web of Science ®Google Scholar
• Munton RP, Tweedie-Cullen R, Livingstone-Zatchej M, et al. Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics. 2007;6:283–293.
   PubMed Web of Science ®Google Scholar
• Steen H, Jebanathirajah JA, Rush J, et al. Phosphorylation analysis by mass spectrometry: myths, facts, and the consequences for qualitative and quantitative measurements. Mol Cell Proteomics. 2006;5:172–181.
   PubMed Web of Science ®Google Scholar
• Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods. 2012;9:555–566.
   PubMed Web of Science ®Google Scholar
• Domanski D, Murphy LC, Borchers CH. Assay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: application to breast cancer signaling pathways. Anal Chem. 2010;82:5610–5620.
   PubMed Web of Science ®Google Scholar
• Britton DJ, Scott GK, Schilling B, et al. A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells. J Am Soc Mass Spectrom. 2008;19:729–740.
   PubMed Web of Science ®Google Scholar
• Lesur A, Ancheva L, Kim YJ, et al. Screening protein isoforms predictive for cancer using immunoaffinity capture and fast LC-MS in PRM mode. Proteomics Clin Appl. 2015;9:695–705.
   PubMed Web of Science ®Google Scholar
• Law KP, Lim YP. Recent advances in mass spectrometry: data independent analysis and hyper reaction monitoring. Expert Rev Proteomics. 2013;10:551–566.
   PubMed Web of Science ®Google Scholar
• Schubert OT, Gillet LC, Collins BC, et al. Building high-quality assay libraries for targeted analysis of SWATH MS data. Nat Protoc. 2015;10:426–441.
   PubMed Web of Science ®Google Scholar
• Schilling B, Rardin MJ, MacLean BX, et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics. 2012;11:202–214.
   PubMed Web of Science ®Google Scholar
• Held JM, Schilling B, D’Souza AK, et al. Label-free quantitation and mapping of the ErbB2 tumor receptor by multiple protease digestion with data-dependent (MS1) and data-independent (MS2) acquisitions. Int J Proteomics. 2013;2013:1–11.
   Google Scholar
• Doerr A. Mass spectrometry-based targeted proteomics. Nat Methods. 2013;10:23.
   PubMed Web of Science ®Google Scholar
• Gallien S, Duriez E, Crone C, et al. Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics. 2012;11:1709–1723.
   PubMed Web of Science ®Google Scholar
• Peterson AC, Russell JD, Bailey DJ, et al. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics. 2012;11:1475–1488.
   PubMed Web of Science ®Google Scholar
• Gallien S, Domon B. Detection and quantification of proteins in clinical samples using high resolution mass spectrometry. Methods. 2015;81:15–23.
   PubMed Web of Science ®Google Scholar
• Andre F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15:267–274.
   PubMed Web of Science ®Google Scholar
• S Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–1334.
   PubMed Web of Science ®Google Scholar
• Hembrough T, Thyparambil S, Liao WL, et al. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. J Mol Diagn. 2013;15:454–465.
   PubMed Web of Science ®Google Scholar